Autologous bone marrow transplantation for patients with acute myeloblastic leukemia in relapse after autologous blood stem cell transplantation.

Abstract:

:Leukemic relapse remains the most frequent reason for treatment failure in patients with acute myeloblastic leukemia (AML) treated with autologous blood stem cell transplantation (ABSCT). The aim of this study was to evaluate the possible role of autologous bone marrow transplant (ABMT) in patients with AML who relapse after ABSCT. Eighteen consecutive patients were enrolled in the study. At ABMT, 17 patients were in untreated relapse and one was in third complete remission (CR). The preparative regimen was BAVC, and consisted of BCNU 800 mg/m2 on day -6, M-AMSA 150 mg/m2/day on days -5 to -3, VP-16 150 mg/m2/day on days -5 to -3 and Ara-C 300 mg/m2/day on days -5 to -3. There were two regimen-related deaths (11%). Thirteen out of 17 patients in untreated relapse before ABMT achieved CR (76%). The cumulative risk of relapse was 58 +/- 13% at 3 years. Seven patients are in CR between 7+ and 53+ months, with a disease-free survival (DFS) probability of 36 +/- 12% at 3 years. The probability of DFS after ABMT was clearly higher in those patients relapsing later than 7 months after the first autograft (52%) than in patients relapsing earlier (20%)(P = 0.02). In a significant proportion of patients, remission duration was clearly longer after ABMT than ABSCT. We conclude that BAVC conditioning followed by ABMT is associated with a low treatment-related toxicity and results in prolonged DFS in a substantial number of AML patients who relapse after ABSCT. Until better therapeutic options become available, ABMT in untreated relapse is a useful alternative in this group of very poor-risk patients.

journal_name

Bone Marrow Transplant

authors

de la Rubia J,Sanz GF,Martín G,Sempere A,Picón I,Carral A,Larrea L,Martínez J,Soler MA,Bonanad S,López F,Jarque I,Sanz MA

subject

Has Abstract

pub_date

1996-12-01 00:00:00

pages

1167-73

issue

6

eissn

0268-3369

issn

1476-5365

journal_volume

18

pub_type

临床试验,杂志文章
  • Caspase-8 polymorphisms result in reduced Alemtuzumab-induced T-cell apoptosis and worse survival after transplantation.

    abstract::Allo-SCT using unrelated donors is a curative treatment for patients with hematological disorders. The best donor is one matched for 10/10 HLA alleles, however studies have shown an additional survival benefit when considering other genetic factors. It has been shown that a six-nucleotide insertion/deletion polymorphi...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1038/bmt.2014.238

    authors: Shaw BE,Lee F,Krishnamurthy S,Byrne JL,Seedhouse C,Mayor NP,Maldonado-Torres H,Saudemont A,Marsh SG,Madrigal JA,Russell NH

    更新日期:2015-02-01 00:00:00

  • Extensive clonal expansion of T lymphocytes causes contracted diversity of complementarity-determining region 3 and skewed T cell receptor repertoires after allogeneic hematopoietic cell transplantation.

    abstract::We previously described skewed repertoires of the T cell receptor-beta chain variable region (TCRBV) and the TCR-alpha chain variable region (TCRAV) soon after allogeneic hematopoietic cell transplantation. To determine the characteristics of skewed TCRBV after transplantation, we examined the clonality of T lymphocyt...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1702858

    authors: Hirokawa M,Matsutani T,Horiuchi T,Kawabata Y,Kitabayashi A,Yoshioka T,Tsuruta Y,Suzuki R,Miura AB

    更新日期:2001-03-01 00:00:00

  • In vivo cytokine responses to interleukin-2 immunotherapy after autologous stem cell transplantation in children with solid tumors.

    abstract::The potent immunostimulatory cytokine interleukin-2 (IL-2) has been extensively investigated for its potential to induce anti-tumor immunity in a number of tumor models. Only recently the complex interplay of mutually suppressive or supportive cytokines of the IL-2-induced network of cytokines has been better characte...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章

    doi:10.1038/sj.bmt.1702431

    authors: Bönig H,Laws HJ,Wundes A,Verheyen J,Hannen M,Kim YM,Banning U,Nürnberger W,Körholz D

    更新日期:2000-07-01 00:00:00

  • Successful treatment of severe hemorrhagic cystitis after hemopoietic cell transplantation by selective embolization of the vesical arteries.

    abstract::Hemorrhagic cystitis (HC) is a common and sometimes life-threatening complication of hemopoietic cell transplantation (HCT) occurring in 7-52% of transplant recipients. In this setting it is usually either related to the use of cyclophosphamide or to a viral infection (BK, JC viruses and adenovirus type 11). Treatment...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1703954

    authors: Giné E,Rovira M,Real I,Burrel M,Montaña J,Carreras E,Montserrat E

    更新日期:2003-05-01 00:00:00

  • Pulse cyclophosphamide for corticosteroid-refractory graft-versus-host disease.

    abstract::Corticosteroid-resistant GVHD is difficult to manage and is associated with high morbidity and mortality. Cyclophosphamide (Cy) is an established immunosuppressive and cytotoxic drug widely used as part of pretransplant conditioning regimens. In a retrospective study of 15 patients who had not responded to corticoster...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1704829

    authors: Mayer J,Krejcí M,Doubek M,Pospísil Z,Brychtová Y,Tomíska M,Rácil Z

    更新日期:2005-04-01 00:00:00

  • Comparison between filgrastim and lenograstim plus chemotherapy for mobilization of PBPCs.

    abstract::Recombinant human (rHu) G-CSF has been widely used to treat neutropenia and mobilize PBPCs for their autologous and allogeneic transplantation. It shortens neutropenia and thus reduces the frequency of neutropenic fever. We compared the efficiency of glycosylated rHu and non-glycosylated Hu G-CSF in mobilizing hematop...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2009.150

    authors: Ria R,Gasparre T,Mangialardi G,Bruno A,Iodice G,Vacca A,Dammacco F

    更新日期:2010-02-01 00:00:00

  • Ocular surface and tear functions after topical cyclosporine treatment in dry eye patients with chronic graft-versus-host disease.

    abstract::We investigated the effect of 0.05% topical cyclosporine (Cys) on the ocular surface and tear functions in dry eye patients with chronic GVHD (cGVHD) in a prospective comparative study. Thirty eyes of 15 patients refractory to baseline treatment were recruited and the patients assigned for topical Cys treatment group ...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章

    doi:10.1038/sj.bmt.1705900

    authors: Wang Y,Ogawa Y,Dogru M,Kawai M,Tatematsu Y,Uchino M,Okada N,Igarashi A,Kujira A,Fujishima H,Okamoto S,Shimazaki J,Tsubota K

    更新日期:2008-02-01 00:00:00

  • A dose escalation study of total body irradiation followed by high-dose etoposide and allogeneic blood stem cell transplantation for the treatment of advanced hematologic malignancies.

    abstract::Since approximately 30% of leukemia patients relapse after allogeneic BMT using total body irradiation (TBI)-based preparative regimens, treatment intensity may be suboptimal. The killing of leukemia cells is proportional to the radiation absorbed dose. We studied the feasibility and toxicity of escalating the doses o...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,多中心研究

    doi:10.1038/sj.bmt.1702230

    authors: Sobecks RM,Daugherty CK,Hallahan DE,Laport GF,Wagner ND,Larson RA

    更新日期:2000-04-01 00:00:00

  • Plasmodium vivax malaria after autologous bone marrow transplantation: an unusual complication.

    abstract::We report the case of unusually early infection by Plasmodium vivax after autologous bone marrow transplantation in a 20-year-old female from Bangladesh affected by acute myelogenous leukemia in first complete remission (CR) who underwent autologous bone marrow transplantation in our center. During the aplastic phase ...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Salutari P,Sica S,Chiusolo P,Micciulli G,Plaisant P,Nacci A,Antinori A,Leone G

    更新日期:1996-10-01 00:00:00

  • Relationship between TNFA, TNFB and TNFRII gene polymorphisms and outcome after unrelated hematopoietic cell transplantation in a Chinese population.

    abstract::This study aimed to analyze the association between cytokine gene polymorphisms and outcome following allogeneic hematopoietic SCT (allo-HSCT). A total of 138 unrelated donor/recipient pairs who underwent allo-HSCT from 2001 to 2009 were tested for TNFA-1031 (T>C), -863 (C>A), -857 (C>T), -238 (G>A), TNFB+252 (A>G) an...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2010.135

    authors: Xiao HW,Lai XY,Luo Y,Shi JM,Tan YM,He JS,Xie WZ,Li L,Zhu XL,Zhu JJ,Sun J,Wei GQ,Jin L,Liu LZ,Wu KN,Yu XH,Cai Z,Lin MF,Ye XJ,Huang H

    更新日期:2011-03-01 00:00:00

  • Intravenous busulfan for allogeneic hematopoietic stem cell transplantation in infants: clinical and pharmacokinetic results.

    abstract:SUMMARY:High-dose busulfan is an important component of myeloablative regimens. Variable drug exposure may occur following oral administration. Therefore, the use of intravenous busulfan has been advocated. Previous work has suggested a cumulative dosage of 16 mg/kg for haematopoietic transplantation in children less t...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1704209

    authors: Dalle JH,Wall D,Theoret Y,Duval M,Shaw L,Larocque D,Taylor C,Gardiner J,Vachon MF,Champagne MA

    更新日期:2003-10-01 00:00:00

  • Comparing i.v. BU dose intensity between two regimens (FB2 vs FB4) for allogeneic HCT for AML in CR1: a report from the Acute Leukemia Working Party of EBMT.

    abstract::This retrospective analysis compared two regimens of fludarabine combined with i.v. BU 6.4 mg/kg (FB2) or BU 12.8 mg/kg (FB4) for allografting of AML in first CR. A total of 437 patients (median age: 50 years) were administered FB2 (n = 225, 51%) or FB4 (n = 212, 49%). Median follow-up time was 28 months. Use of FB2 r...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,多中心研究

    doi:10.1038/bmt.2014.133

    authors: Kharfan-Dabaja MA,Labopin M,Bazarbachi A,Hamladji RM,Blaise D,Socié G,Lioure B,Bermudez A,Lopez-Corral L,Or R,Arcese W,Fegueux N,Nagler A,Mohty M

    更新日期:2014-09-01 00:00:00

  • Allogeneic or haploidentical HSCT for refractory or relapsed solid tumors in children: toward a neuroblastoma model.

    abstract::New concepts of allogeneic hematopoietic SCT (allo-HSCT) for neuroblastoma and other solid tumors do not rely on escalation of chemotherapy intensity and tumor load reduction but rather on a graft-vs-tumor effect. At this point, this is still an investigational and unusual application of allogeneic transplant, with 78...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,评审

    doi:10.1038/bmt.2008.279

    authors: Kanold J,Paillard C,Tchirkov A,Merlin E,Marabelle A,Lutz P,Rousseau R,Baldomero H,Deméocq F

    更新日期:2008-10-01 00:00:00

  • Endocrine late effects in children who underwent bone marrow transplantation: review.

    abstract::With the increasing use and success of BMT, larger numbers of children survive transplantation. Still, cancer treatment in children causes damage to the endocrine glands, often inducing growth deficiency, pubertal delay and thyroid dysfunction. This paper will deal with some of the most common endocrine disorders rela...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,评审

    doi:

    authors: Cohen A,Rovelli R,Zecca S,Van-Lint MT,Parodi L,Grasso L,Uderzo C

    更新日期:1998-04-01 00:00:00

  • Resolution of psoriasis after allogeneic bone marrow transplantation for chronic myelogenous leukemia: late complications of therapy.

    abstract::Treatment of autoimmune disease with bone marrow transplantation (BMT) is under investigation. A few reports of patients undergoing allogeneic BMT for malignant conditions observed the resolution of psoriasis after BMT, with minimal late morbidity. We describe a patient with chronic myelogenous leukemia (CML) whose ps...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1702703

    authors: Adkins DR,Abidi MH,Brown RA,Khoury H,Goodnough LT,Vij R,Westervelt P,DiPersio JF

    更新日期:2000-12-01 00:00:00

  • (90)Y-ibritumomab tiuxetan followed by reduced-intensity conditioning and allo-SCT in patients with advanced follicular lymphoma.

    abstract::Reduced-intensity conditioning (RIC) hematopoietic SCT (HSCT) is a potentially curative therapeutic option for patients with advanced follicular lymphoma (FL), but disease relapse remains the most common cause of failure. Radioimmunoconjugates administered before RIC allo-HSCT may enhance cytoreduction and allow more ...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章

    doi:10.1038/bmt.2010.339

    authors: Abou-Nassar KE,Stevenson KE,Antin JH,McDermott K,Ho VT,Cutler CS,LaCasce AS,Jacobsen ED,Fisher DC,Soiffer RJ,Alyea EP,Koreth J,Freedman AS

    更新日期:2011-12-01 00:00:00

  • Successful purging of murine plasmacytoma by mafosfamide (ASTA-Z).

    abstract::Mafosfamide (ASTA-Z) is a chemotherapeutic agent currently in use for in vitro purging of tumor-bearing human BM cells prior to autologous bone marrow transplantation (ABMT). We tested the efficacy of ASTA-Z against mouse plasmacytoma cells MOPC-315 (MOPC), a model of human multiple myeloma. BALB/c mice were injected ...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Weiss L,Slavin G,Reich S,Sidi H,Slavin S

    更新日期:1994-01-01 00:00:00

  • Donor leukocyte infusions in acute lymphocytic leukemia.

    abstract::Donor leukocyte infusion (DLI) has well-documented activity in CML but the role of DLI in other diseases is less well defined. To evaluate the strategy in acute lymphocytic leukemia (ALL) we evaluated 44 ALL patients from 27 centers who were treated with DLI. Patients with persistent or recurrent disease received DLI ...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1702555

    authors: Collins RH Jr,Goldstein S,Giralt S,Levine J,Porter D,Drobyski W,Barrett J,Johnson M,Kirk A,Horowitz M,Parker P

    更新日期:2000-09-01 00:00:00

  • Neurologic complications after allogeneic hematopoietic stem cell transplantation: risk factors and impact.

    abstract::Neurologic complications (NCs) may be a significant source of morbidity and mortality after hematopoietic cell transplantation (HCT). We performed a retrospective study of 263 consecutive patients undergoing allogeneic HCT for hematological malignancies to determine the incidence, risk factors and clinical impact of N...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2017.239

    authors: Dowling MR,Li S,Dey BR,McAfee SL,Hock HR,Spitzer TR,Chen YB,Ballen KK

    更新日期:2018-02-01 00:00:00

  • Amiodarone and cyclophosphamide: potential for enhanced lung toxicity.

    abstract::Antineoplastic therapy can be associated with drug-induced lung toxicity. With the increasing use of amiodarone for cardiac dysrhythmias there is an increasing possibility of its combined use with chemotherapies for various malignancies. We report a patient on long-term amiodarone who developed biopsy-proven drug-indu...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1703039

    authors: Bhagat R,Sporn TA,Long GD,Folz RJ

    更新日期:2001-05-01 00:00:00

  • Reduced-intensity conditioning is a reasonable alternative for Philadelphia chromosome-positive acute lymphoblastic leukemia among elderly patients who have achieved negative minimal residual disease: a report from the Adult Acute Lymphoblastic Leukemia W

    abstract::Reduced-intensity conditioning (RIC) regimens have been widely used for allogeneic hematopoietic cell transplantation (HCT) in elderly patients. After the emergence of tyrosine kinase inhibitor (TKI), most patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph-positive ALL) now achieve negativ...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/s41409-020-0951-0

    authors: Akahoshi Y,Nishiwaki S,Arai Y,Harada K,Najima Y,Kanda Y,Shono K,Ota S,Fukuda T,Uchida N,Shiratori S,Tanaka M,Tanaka J,Atsuta Y,Kako S

    更新日期:2020-07-01 00:00:00

  • High-dose chemotherapy (HDCT) with auto-SCT in children with atypical teratoid/rhabdoid tumors (AT/RT): a report from the European Rhabdoid Registry (EU-RHAB).

    abstract::A retrospective analysis of data from the European Rhabdoid Registry (EU-RHAB) was performed to describe the outcome of children with atypical teratoid/rhabdoid tumors (AT/RT) who underwent high-dose chemotherapy (HDCT) with auto-SCT. Nineteen patients (male, n=15; median age at diagnosis 21 months) were identified. N...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2013.208

    authors: Benesch M,Bartelheim K,Fleischhack G,Gruhn B,Schlegel PG,Witt O,Stachel KD,Hauch H,Urban C,Quehenberger F,Massimino M,Pietsch T,Hasselblatt M,Giangaspero F,Kordes U,Schneppenheim R,Hauser P,Klingebiel T,Frühwald MC

    更新日期:2014-03-01 00:00:00

  • Bacteremias in children receiving hemopoietic SCT.

    abstract::The incidence of bacteremia following hemopoietic SCT (HSCT) changes over time from the procedure. The first 30 days have the highest incidence, both in autologous and allogeneic HSCT recipients. In the following periods, bacteremia is a frequent complication in allogeneic HSCT, especially from alternative donors. Gra...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2008.66

    authors: Castagnola E,Faraci M,Moroni C,Bandettini R,Caruso S,Bagnasco F,Caviglia I,Natalizia AR,de Fazio V,Morreale G,Lanino E,Dini G,Haupt R

    更新日期:2008-06-01 00:00:00

  • Psychological distress of patients undergoing intensified conditioning with radioimmunotherapy prior to allogeneic stem cell transplantation.

    abstract::This is a pilot study comparing the emotional distress of patients receiving an intensified conditioning regimen (radioimmunotherapy=RIT) with patients receiving conventional conditioning for allogeneic stem cell transplantation. In total, 53 patients (18 received RIT) were given two questionnaires designed to measure...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1704971

    authors: Grulke N,Bailer H,Kächele H,Bunjes D

    更新日期:2005-06-01 00:00:00

  • Monitoring of cyclosporin during continuous intravenous administration.

    abstract::Intravenous cyclosporin was administered continuously to 18 consecutive marrow transplant recipients. Blood samples taken from the single lumen central venous line through which the cyclosporin was administered showed invariably high concentrations. Toxic levels were still present after discontinuation of cyclosporin ...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: de Witte T,Hoitsma A,Manoiu MM,Janssen J

    更新日期:1986-12-01 00:00:00

  • Trajectories of acute graft-versus-host disease and mortality in critically ill allogeneic-hematopoietic stem cell recipients: the Allo-GRRR-OH score.

    abstract::Acute graft-versus-host disease (aGVHD) is a major cause of morbidity mortality in critically ill hematopoietic stem cell transplantation recipients. We assessed aGVHD trajectories in 191 allogeneic-HSCT recipients (age 42 (27-46)) admitted to our ICU between 2005 and 2015. aGVHD affected 130 (68%) patients (including...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/s41409-020-0857-x

    authors: Pichereau C,Lengliné E,Valade S,Michonneau D,Ghrenassia E,Lemiale V,Socié G,Azoulay E

    更新日期:2020-10-01 00:00:00

  • Incidence and outcome of Clostridium difficile infection following autologous peripheral blood stem cell transplantation.

    abstract::A retrospective evaluation of 200 consecutive recipients of autologous peripheral blood stem cell transplantation (PBSCT) was conducted to ascertain the incidence and outcome of infection with Clostridium difficile. The diagnosis was confirmed in 14 patients with diarrhea (15 episodes) at a median of 33 days after ste...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1701773

    authors: Bilgrami S,Feingold JM,Dorsky D,Edwards RL,Bona RD,Khan AM,Rodriguez-Pinero F,Clive J,Tutschka PJ

    更新日期:1999-05-01 00:00:00

  • Do patients with metastatic and recurrent rhabdomyosarcoma benefit from high-dose therapy with hematopoietic rescue? Report of the German/Austrian Pediatric Bone Marrow Transplantation Group.

    abstract::Patients with primary metastatic or recurrent rhabdomyosarcoma (RMS) have a very poor prognosis. Since high-dose chemotherapy (HDC) +/- TBI was thought to improve survival, many centers performed this therapy using different types of hematopoietic rescue (auto BM or PBSC, allo BM). This is a retrospective, multi-cente...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,多中心研究

    doi:10.1038/sj.bmt.1700628

    authors: Koscielniak E,Klingebiel TH,Peters C,Hermann J,Burdach ST,Bender-Götze C,Müller-Weihrich ST,Treuner J

    更新日期:1997-02-01 00:00:00

  • Efficiency of allogeneic hematopoietic SCT from HLA fully-matched non-sibling relatives: a new prospect of exploiting extended family search.

    abstract::The best donors for hematopoietic SCT (HSCT) are fully-matched siblings. In patients without fully-matched siblings, HLA registries or cord blood banks are alternative strategies with some restrictions. Owing to the high rate of consanguineous marriage in our country, between 2006 and 2013, extended family searches we...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2014.307

    authors: Hamidieh AA,Dehaghi MO,Paragomi P,Navaei S,Jalali A,Eslami GG,Behfar M,Ghavamzadeh A

    更新日期:2015-04-01 00:00:00

  • The HLA-A*0201-restricted minor histocompatibility antigen HA-1H peptide can also be presented by another HLA-A2 subtype, A*0206.

    abstract::HA-1(H) is one of the most attractive minor histocompatibility antigens (mHA) as a target for immunotherapy of hematopoietic malignancies, but HLA-A*0201 and HLA-B60 molecules capable of presenting HA-1(H)-derived peptides are less common in eastern Asian populations when compared with Caucasian populations. Therefore...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1705689

    authors: Torikai H,Akatsuka Y,Miyauchi H,Terakura S,Onizuka M,Tsujimura K,Miyamura K,Morishima Y,Kodera Y,Kuzushima K,Takahashi T

    更新日期:2007-07-01 00:00:00